Vivian W. Y. Liao

Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies

Nathan L. Absalom, Vivian W. Y. Liao, Katrine M. Johannesen et al. · Nature Communications · 2022 · 83 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Gain-of-function variants in <i>GABRD</i> reveal a novel pathway for neurodevelopmental disorders and epilepsy

Philip K. Ahring, Vivian W. Y. Liao, Elena Gardella et al. · Brain · 2021 · 74 citations · Full text

Life Sciences, Genetics, Neuroscience +17

Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors

Natalia M. Kowal, Philip K. Ahring, Vivian W. Y. Liao et al. · British Journal of Pharmacology · 2018 · 51 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Gain-of-function <i>GABRB3</i> variants identified in vigabatrin-hypersensitive epileptic encephalopathies

Nathan L. Absalom, Vivian W. Y. Liao, Kavitha Kothur et al. · Brain Communications · 2020 · 35 citations · Full text

Medicine, Neurobiology, Neurology +17

The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABAA Receptors Containing γ1, γ2, and γ3 Subunits

G. Richter, Vivian W. Y. Liao, Philip K. Ahring et al. · Frontiers in Neuroscience · 2020 · 35 citations · Full text

Medicine, Neuroscience, Pharmacology +13